Novartis AG (NVS) has been under a strong bear grip, hence the stock is down -0.44% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.34% in the past 1 week. The stock has risen by 0.88% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.46% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 0.72% and the 50-Day Moving Average is 2.58%.The 200 Day SMA reached 1.76% Novartis AG is up 1.84% in the last 3-month period. Year-to-Date the stock performance stands at -4.19%.
Novartis AG (NVS) : The highest short term price target forecast on Novartis AG (NVS) is $115 and the lowest target price is $81. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $92 with a standard deviation of $15.51.
For the current week, the company shares have a recommendation consensus of Buy. Novartis AG (NYSE:NVS): stock was range-bound between the intraday low of $79.13 and the intraday high of $79.64 after having opened at $79.55 on Fridays session. The stock finally closed in the red at $79.55, a loss of -0.68%. The stock remained in the red for the whole trading day. The total traded volume was 1,111,327 shares. The stock failed to cross $79.64 in Fridays trading. The stocks closing price on Thursday was $79.34.
Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.